Who are Rocklatan 0.02%-0.005% Ophthalmic Solution's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rocklatan-0-02-0-005-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rocklatan 0.02%-0.005% Ophthalmic Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rocklatan 0.02%-0.005% Ophthalmic Solution (Rocklatan 0.02%-0.005% Ophthalmic Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog / Rho kinase inhibitor combination. Area: Ophthalmology.

marketed Prostaglandin analog / Rho kinase inhibitor combination Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Rocklatan 0.02%-0.005% Ophthalmic Solution (Rocklatan 0.02%-0.005% Ophthalmic Solution) — Eye Centers of Southeast Texas. Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocklatan 0.02%-0.005% Ophthalmic Solution TARGET	Rocklatan 0.02%-0.005% Ophthalmic Solution	Eye Centers of Southeast Texas	marketed	Prostaglandin analog / Rho kinase inhibitor combination	Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog / Rho kinase inhibitor combination class)

Eye Centers of Southeast Texas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rocklatan 0.02%-0.005% Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/rocklatan-0-02-0-005-ophthalmic-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab